These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 24518563)

  • 1. Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment.
    D'Eufemia P; Finocchiaro R; Villani C; Zambrano A; Lodato V; Palombaro M; Properzi E; Celli M
    Pediatr Res; 2014 May; 75(5):626-30. PubMed ID: 24518563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.
    D'Eufemia P; Finocchiaro R; Zambrano A; Lodato V; Celli L; Finocchiaro S; Persiani P; Turchetti A; Celli M
    Osteoporos Int; 2017 Jan; 28(1):339-346. PubMed ID: 27562566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous neridronate in adults with osteogenesis imperfecta.
    Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
    J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.
    D'Eufemia P; Finocchiaro R; Celli M; Zambrano A; Tetti M; Villani C; Persiani P; Mari E; Zicari A
    Pediatr Res; 2008 Feb; 63(2):203-6. PubMed ID: 18091347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1.
    Faienza MF; Tummolo A; Celli M; Finocchiaro R; Piacente L; Di Serio F; Nicchia GP; Brunetti G; D'Eufemia P
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
    Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
    Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH in combination with bisphosphonate treatment in osteogenesis imperfecta.
    Antoniazzi F; Monti E; Venturi G; Franceschi R; Doro F; Gatti D; Zamboni G; Tatò L
    Eur J Endocrinol; 2010 Sep; 163(3):479-87. PubMed ID: 20592128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
    Rauch F; Travers R; Plotkin H; Glorieux FH
    J Clin Invest; 2002 Nov; 110(9):1293-9. PubMed ID: 12417568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
    Rauch F; Plotkin H; Zeitlin L; Glorieux FH
    J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B; Aström E; Söderhäll S
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
    Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
    Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.